Ozempic is a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Fiasp is a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.
Both medications received approval from the US Food and Drug Administration in 2017 and represent the latest advancements to Novo Nordisk's diabetes portfolio.
Novo Nordisk is a diabetes care specialist that is also focused on other serious chronic conditions such as hemophilia, growth disorders, and obesity. The company has nearly 5,000 employees in the US.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid